Trial Profile
A Multicenter, Randomized, Double-Blind, Bilateral, Vehicle-Controlled Study of the Safety and Efficacy of ALX-101 Topical Gel Administered Twice Daily in Adult and Adolescent Subjects With Moderate Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Nov 2018
Price :
$35
*
At a glance
- Drugs ALX 101 (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Ralexar Therapeutics
- 23 Oct 2018 Status changed from recruiting to completed.
- 05 Jun 2017 New trial record